Pritzker takes aim at Trump tariffs with business tours, calls to foreign officials
The duties on Mexico and Canada were 'paused' by Monday afternoon amid negotiations between the nation's leaders, but that didn't stop Gov. JB Pritzker from frequently taking aim at the tariffs — and Trump — this week.
On Friday, at an announcement of a new tax credit for Freedman Seating, a Chicago-based vehicle seat manufacturer, Pritzker criticized the president's attempts to impose the tariffs.
'Affordability and jobs are potentially the victims of that trade war,' Pritzker said. 'Tariffs are a tax paid for by consumers. In the end, it's a tax on working families and on small businesses.'
Freedman Seating agreed to invest $4 million for capital upgrades at its Chicago facility and is set to get a state tax credit as part of a deal to create 50 new jobs and keep 676 existing ones. The deal is part of Illinois' Economic Development for a Growing Economy program.
That company was the latest Pritzker visited in what became a week of campaigning against the tariffs. On Thursday, he visited Darvin Furniture in Orland Park and Funkytown Brewery in Chicago to discuss the proposed duties. The furniture store already put a hold on a deal with a Canadian supplier, according to Pritzker's office.
Trump's reasons for the tariffs aren't relevant to Canada, Pritzker argued Friday.
'With regard to Canada, 1% of all the fentanyl that ends up in the United States is coming from the northern border, from Canada,' he said. 'One percent, that's the emergency he's going after. Immigration is the second of the two emergencies that he has declared in order to put these tariffs on. Immigration — that is not a problem from Canada.'
On Wednesday, Pritzker called Canadian Ambassador to the U.S. Kirsten Hillman and Consul General of Mexico in Chicago Reyna Torres Mendivil to discuss the tariffs. On Friday, he said he urged them to make sure their respective countries 'don't retaliate' against products that are important to companies in Illinois.
Pritzker also went after Trump's disbandment of diversity, equity, and inclusion frameworks, calling the move an attack on civil rights during Friday's news conference. And he criticized the Trump administration's federal funding freeze, saying it was actually a freeze on programs that keep Illinois safe, specifically local law enforcement agencies.
'It's a massive effort to distract from what they are doing across the country, to take away things that working-class, middle-class people, families, and the most vulnerable really need,' he said.
Trump's actions may also pump the brakes on one of Pritzker's signature policy goals: reducing the state's carbon footprint.
Pritzker set a goal to have 1 million electric vehicles on Illinois roads by 2030. Pritzker's administration has also awarded more than $1.1 billion in tax breaks meant to bolster the EV industry supply chain since 2022.
But that effort could face new headwinds after the Trump administration told states Thursday it was suspending funding for the National Electric Vehicle Infrastructure program, a Biden-era program that was originally designed to put $5 billion toward building new EV chargers.
The Illinois Department of Transportation, which administers the program in Illinois, announced in September that it approved $25 million for the first round of funding. Illinois was set to receive as much as $148 million in total through 2027 as part of the program.
Drive an electric vehicle in the metro-east? Here's where you can charge up for free
Late last year, the department extended the application window for the second round and was accepting applications as recently as this week, according to its website.
Pritzker also on Thursday took on a new role as co-chair of 'America is All In,' an advocacy group aimed at a 'whole-of-society' response to climate change.
It originated during the first Trump administration after state elected officials and business leaders — including Pritzker — wanted to signal that they would still take aggressive action on climate change after Trump said he would pull the U.S. out of a 2016 U.N. agreement committing the nation to reducing its carbon emissions.
'We cannot be afraid to tell the truth: the climate crisis is real and we must tackle it with action that protects us from natural disasters and builds a strong clean energy economy with good-paying jobs,' Pritzker said in a statement 'It's clear that states like Illinois and cities, businesses, and institutions will be where climate action presses forward.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Why Investors Were So Fired Up About First Solar Stock on Friday
Key Points Data center operators are unhappy with potential changes to federal incentives for green energy solutions. A group of them are lobbying the Trump administration to leave these incentives alone for now. 10 stocks we like better than First Solar › The solar industry has struggled mightily for years to achieve meaningful growth and post net profits. During the Biden administration, the green energy sector as a whole received something of a break in the 2022 Inflation Reduction Act, with a slew of tax incentives for building out alternative-energy solutions. In its attempt to reverse this, President Donald Trump has tasked his administration to make the current subsidies harder to obtain. Thankfully for green energy companies, a theoretically influential lobbying group stepped in on Friday to push back against this effort. Numerous solar stocks popped on the news, including First Solar (NASDAQ: FSLR), which rose a sturdy 11% by market close. A mighty lob by a lobbying group The business grouping behind Friday's pushback is the Data Center Coalition. News broke that the coalition sent a formal request to Treasury Secretary Scott Bessent to maintain the subsidy policy as it is, rather than changing it. The organization -- which lists as members Amazon, Oracle, and CoreWeave, among other prominent tech companies -- told Bessent that any regulatory roadblock limiting green energy solutions will hamper the development of artificial intelligence (AI). Many data center operators are currently building out their facilities to handle the vastly increased resource demands of AI. To do so, they require more energy, hence their support of renewable sources like solar. Does the silence speak volumes? Bessent hasn't yet publicly responded to the coalition's lobbying effort, nor has anyone else in the Trump administration. But investors seem convinced that they've not only digested the letter, they're taking it seriously, since the organization behind it has many prominent members who drive the U.S. economy. Should you invest $1,000 in First Solar right now? Before you buy stock in First Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and First Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, First Solar, and Oracle. The Motley Fool has a disclosure policy. Why Investors Were So Fired Up About First Solar Stock on Friday was originally published by The Motley Fool
Yahoo
40 minutes ago
- Yahoo
Carvana (CVNA) Expands Same-Day Delivery to Chicago, Enhances Vehicle Network
Carvana Co (NYSE:CVNA) is one of the best growth stocks to buy according to analysts. On August 14, Carvana Co (NYSE:CVNA) announced that it is expanding its same-day vehicle delivery service to the greater Chicago area. Carvana offers an online car-buying platform, where customers can browse vehicles, complete financing, and finalize their purchase without having to go to a dealership. With same-day delivery, buying a car through Carvana could become incredibly convenient. The company said that this is just one of the many steps it has been taking to expand faster delivery options across the country. For example, Carvana has been using some of the ADESA (an acquisition it made a few years ago) locations as places where cars get cleaned up, inspected, and made ready for sale, among other things. This is helping improve efficiency at the company. The company said that as of the end of the second quarter of 2025, it had fully integrated 12 ADESA locations into its network. It said that these moves have helped them grow their ability to recondition more cars and offer a wider selection of vehicles to their clients. While we acknowledge the potential of CVNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
42 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.